evaxion.ai Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-ImmunologyTM. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-ImmunologyTM, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-ImmunologyTM platform and vaccine …

Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

70 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Antibody Bioengineered atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company …

59 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune …

12 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and …

27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

160 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small …

4 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your key partner for breakthrough antibody discovery Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities. Antibody Discovery, Fully Human …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ready -to -use cell bank, for research, for patients Lymphobank - Bank of ready -to -use cells, for research, for patients. Lymphobank is a biotech specializing in the supply of adult and placental -use -for -use blood cells, the characteristics of which will be available online (www.lymphobank.fr), allowing the cellular product to be chosen according to an interest donor. Our services are focused on the development of cellular immunotherapy products. In addition, Lymphobank develops an innovative approach to allogenic adoptive immunotherapy of hepatocellular carcinoma (the most frequent liver cancers and second cause of cancer death in the world, with nearly …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering Patient-led Antibody Therapeutics Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease. Antibody Therapies, Immunology, and Neuro-dengeneration

34 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

30 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerate your way to the clinic ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined …

17 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ArkAb is now Bcell Design! ArkAb is now Bcell Design! Bcell Design develops and manufactures chimeric monoclonal antibodies with human-like characteristics for in vitro diagnostics. We provide a secure and reliable source of raw material as a best alternative to disease state plasma and human serum, currently used as calibrators, positive controls or quality controls. Through its technological platform, built upon 15 years’ expertise in mAb and early-stage immunotherapy development, IVD developers and manufacturers gain access to a wide range of antibodies that are immediately ready for testing in human models. Founded in 2007 and from one of the few …

7 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The next generation of of single domain antibodies Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

EXIST Start-up Project Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies. Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete. Have a look at our website for further information and …

9 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our specificity, your antibodies Pioneer in antibodies’ field, Agro-Bio provides you its expertise and its know-how for production, development and characterization of antibodies. For over 40 years, our team supports pharmaceutical and in vitro diagnostic industries as well as public institutions for their immunology issues. We collaborate both to offer you the most suitable and effective solution. Our goal is the success of your projects. Our services around antibody: • Bioanalysis/Biopharma: o Anti-idiotypic antibodies for positive control, PK and potency test, o Host Cell Protein issue management: specific anti-HCP antibodies, 2D Western Blot coverage analysis, specific ELISA kit, o Epitope …

26 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website. The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the …

44 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Biomanufacturing, development & analytical services: Plasmids, Antibodies, Recombinant proteins, Cells - FastELISA kits French CRO Biotechnology 🔎 BIOMANUFACTURING: Plasmids (R&D and High Quality grades, And Now a pDNA GMP unit), Monoclonal antibodies, Recombinant antibodies (scFV, Fab, bispecific...), recombinant proteins (E.Coli, Cell free system, Yeast and mammalian cells), cells. 💡 Antibody engineering & molecular biology platforms: Antibody sequencing, vector design & cloning, Recombinant antibody production, Chimerization and Humanization, cell line development... ✍ Analytical services: immunoassays development, antibody characterisation, quality controls (R&D and high quality grades) FastELISA kits: Immunoglobulin quantification (human, mouse, rat, bovine), Mouse Immunoglobulin isotyping, Contaminant detection (Protein A), other …

80 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailor designed to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis

49 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advanced Antibody Expertise Deeptope's expertise lies in antibody charaterisation (epitope/paratope mapping) and optimisation using high throughput methods. antibody, paratope mapping, epitope mapping, and antibody optimisation

77 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries

62 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

294 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Design, Production, and Delivery of Antibodies – Reimagined by AI Genotic utilizes AI for the rapid design and production of customized antibodies for all kinds of targets. Our fully computational, animal-free approach guarantees high quality and delivers solutions within weeks, not years. biotechnology, machine learning, and antibody

59 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I.

Innovative start up developing monoclonal antibodies in cancer and inflammatory diseases MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

114 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1). Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1. immunologie and oncologie

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Maximizing Immunoassays Performances InfYnity Biomarkers was founded in 2009 in Lyon (France). We are an R&D In-Vitro Diagnostics Company fully dedicated to infectious diseases and immunity. Company Mission: Maximizing Immunoassay Performance i.e. we have the ambition to set new criteria for immunoassays: study the diversity of immune response to provide high-value information instead of the binary response. Our Offer: - High quality, custom-made biomaterial (antigens and antibodies) - RUO Multiplex Immunoassays - Tailored immunobiology services ranging from biomaterial design to biomarker discovery and immunoassay development. Our originality and strength relies on a unique combination of proven skills: Multiplex technology AND …

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

First-in-class immunomodulatory peptides. Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need. immunodermatology, peptides, inflammatory diseases, respiratory diseases, inflammation, and immunomodulation

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering Value Through the Power of Plants Serendip Innovations is a preclinical-stage biotechnology company developing a cutting-edge nanoparticulate delivery platform for active ingredients. We offer co-development partnerships and technology licensing opportunities for applications such as therapeutic and prophylactic vaccines, as well as precision medicine. What sets us apart is the high modularity of our platform, enabling the custom design of a new generation of targeted therapeutics. As a first application, Serendip is addressing the challenges of therapeutic cancer vaccines by transforming its platform into a high-performance immunization system. This system enhances the presentation of tumor antigens and elicits strong anti-tumor …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Personalized Immunotherapy to Treat Cancer Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has …

31 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Unlocking New Immunotherapy Paths with Smart Peptides SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology. SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most. SPIMA Therapeutics is part of the nexus of Landmark Bioventures. Join us in shaping the future of medicine, where discovery meets dedication. Immunothery

23 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Plant-based Nanotechnologies for autoimmune diseases diagnoses and therapy DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has …

55 similar entities Type: Startup Activities: nanotech biotech deeptech healthtech Technologies: Synthetic Biology

The only TechBio providing computationally designed antibodies through AI with biological validations associated MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery. We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies. While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation. Using NLP technologies we gather information …

Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Natural Language Processing Synthetic Biology

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective …

Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Unique know-how to discover and engineer novel antibody therapeutics in immunology & inflammation (I&I) and neurology. Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

47 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in immunotechnologies since 1980! Our commitment makes the difference! Expert in immunotechnology, BIOTEM is a contract Research Organisation which complies with ISO 9001:2008 quality standards. Since its establishment in 1980, the company has been the privileged partner of prestigious industrial and academic laboratories for their R&D, diagnostic and therapeutic projects. Based on a high level of expertise and exclusive technologies, BIOTEM implements the most relevant strategies for each project and is pledged to achieve the results outlined in the contract. BIOTEM advantages: - Results guaranteed - An unparalleled traceability throughout your project - Optimal quality of your product …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, …

77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discovery of innovative therapeutic antibodies for human and animal health MabGenesis Inc. is a biopharmaceutical company that provides fully species-specific therapeutic antibodies to human and companion animals. We have the world’s highest quality antibody libraries (MOURA Libraries) in terms of functionality and completeness, as well as highly efficient monoclonal antibody isolation technology (IMPACT). By using these, we make it possible to obtain high-affinity monoclonal antibodies that recognize unique 3D structures or subtle structural differences of target molecules such as membrane proteins, thus contributing to new drug development opportunities in the pharmaceutical industry. Biotechnology, Antibody, Monoclonal antibody, VHH, membrane protein, Canine, …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better technology for better health LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK. vaccines, research & development, biotechnology, and antimicrobial resistance

147 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exceptional Human Antibody Discovery Technology Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. We offer the leading in vivo platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation of therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs. We aim to make Trianni’s premium technology available to any Pharma or Biotech company engaged in antibody discovery by offering flexible licenses …

47 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ligandal is developing precision molecular therapeutics and targeted delivery technologies. Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, …

24 similar entities Type: Startup Activities: biotech deeptech healthtech nanotech Technologies: Synthetic Biology

A clinical-stage biotech company that aims to develop the world’s most potent vaccines for cancer and infectious disease Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and …

43 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation focused private biotech dedicated to delivering next-generation multispecific antibody therapeutics. F-star is a private biotech, based in Cambridge UK, focused on using our world-leading, innovative bispecific antibody technology that is clinically validated, patent protected and designed to create therapeutics that help more people with cancer and other serious diseases live longer with improved lives. bispecific antibodies, immuno-oncology, Immmunotherapy, oncology, cancer, tetravalent bispecifics, cancer research, biotech, immunology, CNS, and autoimmunity

74 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We understand disease through the lens of the immune system for more effective, safer treatments & better diagnosis Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A new generation of vaccines based on fusions of recombinant proteins A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Veterinary, Vaccines, Animal Health, Biotech, Recombinant Vaccines, Veterinary Products, Microbiology, Wholesale, and Research and Development

114 similar entities Type: Startup Activities: manufacturing healthtech deeptech Technologies: Synthetic Biology

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical …

67 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineered Immunity Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmune diseases. Our immune checkpoint activators protect patient’s organ tissue. Unique approach : - Potential for BEST-in-class super agonist against immune-mediated tissue damage - High selectivity for active T-cells - Proof of concept in relevant human in vitro models and mouse model of disease

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their …

70 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology

Antibody discovery engine AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell engagers, and Bispecifics

70 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Changing the world, one sequence at a time. Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology …

76 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Cancer Immunotherapy At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer. Biotech, Therapeutics, and Immuno-oncology

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapies for inflammatory disease and cancer by targeting fibroblast immunology Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career. biotechnology, fibroblasts, oncology, immuno oncology, inflammatory disease, and datascience

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

170 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Integrating human biology with machine learning for antibody discovery Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXISTM, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com. Lymph Node Organoids, Immunogenicity Screening, Human Antibody Discovery, and Antibody Discovery

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your trusted partner for innovative, end-to-end antibody services At FairJourney Biologics, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 14 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in immunology projects! ImmunXperts a Q2 Solutions Company, your partner for what’s next in assay and biomarker development, advanced laboratory testing, and translational immunology. ImmunXperts brings an unrivaled ability to efficiently develop immunogenicity and immuno-oncology in vitro assays – to address both wanted and unwanted immunity for novel modalities. Immunogenicity Assessment, Immune Academy, Training, Consultancy, immuno-oncology, Cell Therapy, In vitro, assay development, Primary cells, Immunogenicity, and Immunology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Kymab, a Sanofi company, based in Cambridge UK, is working to provide novel solutions in drug and vaccine development. Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with …

26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. Machine Learning, Antibodies, and Drug discovery

104 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology

Antibody Services from Discovery to Clinical Supply Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of …

38 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

BigHat Biosciences is a novel protein therapeutics company and developer of an AI-guided antibody design platform BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids …

62 similar entities Type: Startup Activities: biotech deeptech it services Technologies: A.I. Synthetic Biology SaaS Generative A.I.

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Creating class-leading ADCs with enhanced tumor specificity Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety. Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic …

31 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Designing novel proteins, enzymes, and antibodies is limited by the problem of generating and screening vast mutational sequence space. Revolve addresses this problem with our patented library generation platform producing custom DNA libraries with unparalleled efficiency. The company has developed an ultra-affinity antibody discovery engine based on this library platform and has a pipeline of protein products in development. Custom mutagenesis libraries, Protein Engineering, Protein Libraries, and Antibody Engineering

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining ADCs. Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets. Antibody Drug Conjugates, Targeted Therapy, Biotechnology, and Drug Development

31 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We fight for human health - we are the RNA people CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics …

33 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Designing and delivering cell therapies to transform the lives of people with cancer. Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

62 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology